SuperworthPrelude Therapeutics PRLD
- Market cap
- $289.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 12.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $22.4M
- +220% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −11.5%
Prelude Therapeutics trades at 12.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $22.4M over the last twelve months, up 220% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | $3M | $4M | $0 | $0 | $6.5M+117% | $5.6M+41% | $4.6M | $5.7M | |
| R&D | $26.3M+15% | $30.3M+17% | $27.4M+26% | $29.5M+18% | $29.5M+12% | $31.6M+4% | $28.8M+5% | $25.8M−13% | $21.7M−26% | $18M−43% | $13.6M−53% | $16.1M−37% |
| SG&A | $7.1M−5% | $7M−6% | $6.9M−5% | $7.7M+3% | $7.9M+11% | $6.2M−12% | $5.8M−17% | $6.4M−16% | $5.2M−34% | $5M−20% | $5.2M−11% | $5M−22% |
| −$33.4M+10% | −$37.4M+12% | −$34.3M+18% | −$37.2M+15% | −$34.4M+3% | −$33.8M−10% | −$34.6M+1% | −$32.2M−13% | −$20.4M−41% | −$17.3M−49% | −$14.2M−59% | −$15.5M−52% | |
| Net income | −$30.6M+2% | −$33.1M+16% | −$31.4M+13% | −$34.7M+14% | −$32.3M+5% | −$28.7M−13% | −$32.1M+2% | −$31.2M−10% | −$19.7M−39% | −$16.5M−43% | −$10.4M−68% | −$13.9M−55% |
| −$0.45−29% | −$0.48−20% | −$0.42−28% | −$0.46−15% | −$0.43−4% | −$0.38−21% | −$0.42+0% | −$0.41−11% | −$0.26−40% | −$0.21−45% | −$0.13−69% | −$0.14−66% | |
| 67.6M+43% | 69.5M+46% | 75.7M+59% | 75.8M+35% | 75.9M+12% | 75.9M+9% | 76M+0% | 76M+0% | 76.1M+0% | 79.7M+5% | 82.5M+9% | 98.4M+30% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Prelude Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PRLDPrelude Therapeutics | $289.7M | n/m | n/a | 12.9× | +220% | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $577.1M | 13.3× | 17.0× | 1.5× | +7% | 11.2% |
More on Prelude Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .